Frontlight ResearchEarly access
CompletedNo phase
Surgical Implantation of TRAnscatheter vaLve in Native Mitral Annular Calcification (SITRAL) Study
Key facts
- Who runs it
- Baylor Research Institute
- Where
- Baltimore, Charlottesville, Houston, Indianapolis, Plano, and Wynnewood, United StatesSee the 6 sites
- Trial code
- Status
- Completed
- People taking part
- 25 people enrolled
- Started
- 4 Nov 2016
- Ended
- 29 Nov 2023
- Type of study
- Interventional
- Treatments tested
- Mitral Valve Replacement (MVR) with Sapien3
- Record updated
- 24 February 2025
Who can take part
- Age
- 22 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Subject has severe native mitral annular calcification associated with mitral stenosis and/or regurgitation. Qualifying echo must be within 60 days of the date of the procedure
- Subject has a clinical indication for mitral valve replacement, as demonstrated by reported New York Heart Association (NYHA) Functional Class II or greater
- The subject is at least 22 years old
- The Heart Team agrees that the subject is high risk or inoperable for surgical mitral valve repair or replacement (MVR), based on a conclusion that the probability of death or serious, irreversible morbidity exceeds the probability of meaningful improvement. The following concomitant procedures, are allowed: Maze, Tricuspid Valve Procedures (TVP), and Atrial Fibrillation (AF) ablation, coronary artery bypass grafting and septal myectomy
- The study subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB) of the respective clinical site
- The study subject agrees to comply with all required post-procedure follow-up visits
Who cannot take part
- Evidence of an acute myocardial infarction (MI) ≤ 30 days before the intended treatment [defined as: Q wave MI, or non-Q wave MI with total creatine kinase (CK) elevation of creatine kinase-myocardial band (CK-MB) ≥ twice normal in the presence of myocardial band (MB) elevation and/or troponin level elevation (WHO definition)]
- Any therapeutic invasive cardiac procedure resulting in a permanent implant that is performed within 30 days of the index procedure (unless part of planned strategy for treatment of concomitant coronary artery disease)
- Hemodynamic or respiratory instability requiring vasoactive medications, mechanical ventilation at time of procedure
- Need for emergency surgery for any reason
- Active upper gastrointestinal (GI) bleeding within 3 months prior to procedure without treatment or 30 days prior to procedure with definitive treatment
- A known contraindication or hypersensitivity to all anticoagulation regimens, or inability to be maintained on oral anticoagulant following the study procedure
- End stage renal disease requiring dialysis
- Clinically (by neurologist) or neuroimaging confirmed stroke or transient ischemic attack (TIA) within 30 days of the procedure
- Leukopenia (white blood cell count < 2000 cell/mL), acute anemia (hemoglobin < 8 g/dL), or thrombocytopenia (platelet count < 50,000 cell/mL)
- Severe left ventricular dysfunction with Left Ventricular Ejection Fraction (LVEF) < 30%
- Severe right ventricular dysfunction
- Pregnancy, lactation, or planning to become pregnant
- Echocardiographic evidence of left ventricular mass, thrombus, or concerns of active infective endocarditis
- Estimated life expectancy < 12 months
Where in United States
- MHRI MarylandBaltimore, United States
- University of VirginiaCharlottesville, United States
- Baylor College of MedicineHouston, United States
- St. Vincent Heart CenterIndianapolis, United States
- The Heart Hospital Baylor PlanoPlano, United States
- Lankenau Institute for Medical ResearchWynnewood, United States
About the trial
What the trial wants to find out
The purpose of this study is to establish the safety and feasibility of the Edwards SAPIEN 3 valve in subjects with mitral annular calcification (MAC) associated with mitral stenosis (MS) and/or mitral regurgitation who are at high-risk for mitral valve surgery or deemed inoperable due to the extent of calcification.
The group in the trial
- Mitral Valve Replacement (MVR) with Sapien3Treatment being tested
subjects with surgical MVR with Sapien3
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 24 February 2025